The novel molecular endometrial cancer classifier, ProMisE, provides independent prognostic information beyond established clinicopathologic risk factors. The aim of this study was to correlate the ProMisE sub groups to sonographic findings and to correlate preoperative clinical, sonographic, and molecular variables to the risk of recurrence/progression. Methods: We prospectively included 340 women with endometrial cancer undergoing expert ultrasound (US) assessment according to the IETA. All women underwent hysterectomy and were followed-up for at least 26 months. Tumours were graded and staged according to FIGO, and ProMisE (MSI, POLE, p53 abn, p53wt). Univariable and multivariable Cox-regression analysis was used to correlate preoperative parameters to recurrence/progression. Results: Women were followed for in mean 38.3 months ). Stage A was found in 60%, ≥ IB in 40%. MSI was found in 35%, POLE 9%, p53abn 12%, and p53wt 44%. Recurrence/progression occurred in 13% (among p53abn in 38%, MSI 13%, POLE 13%, p53wt 6%). p53 abn tumours often had uniform echogenicity (60%), colour score 3-4 (78%), and larger tumour AP diameter (p=0.004) compared to other tumours. Preoperative parameters associated with recurrence/progression were age >65 years (OR 2.9, 95%CI 1.4-6.1), waist circumference (WC) > 88cm (OR 2.6, 95%CI 1.2-5.5), p53abn (OR 4.6, 95%CI 2.5-7.7), and deep myometrial/cervical stromal invasion (OR 4.1, 95%CI 2.2-7.7), or tumour AP diameter > 2 cm (OR 7.5,, according to US. Age > 65, WC > 88cm, tumour AP diameter > 2 cm, and p53 abn remained significant in multivariable analysis. Conclusions: The p53abn subgroup was associated with the highest risk of recurrence/progression. Most p53 abn tumours had a uniform echogenicity, colour score 3-4, and they were significantly larger than other molecular subtypes. In multivariable analysis age, waist circumference, tumour AP diameter and p53 abn tumour type remained important predictors for recurrence/progression.
* This presentation is eligible for the Young Investigator award (to be presented in the closing plenary).
Methods: This is a retrospective review of myomectomies performed between January 2004 and June 2014 in a single surgical unit. Laparoscopic myomectomy was offered to women with ≤3 intramural/submucous myomas and a dominant myoma measuring 5-12cm. The remaining women were offered open myomectomy. Ultrasound findings suggestive of sarcoma were: irregular shaped tumours, blurred margins, necrosis, peritoneal deposits and inability to visualise the endometrial cavity. These women were referred to gynecological oncologists for further management. Results: There were 1261 women presenting with symptomatic fibroids requiring surgery. 17 (1.3%) were diagnosed with uterine sarcoma. 903 women requested abdominal myomectomy. 514/903 (56.9%) of them were scheduled for laparoscopy and 389/903 (43.1%) women had open myomectomy. Final histology confirmed a sarcoma in 12/17 (70.6%) women with ultrasound diagnosis of malignancy. In addition, 1/389 (0.3%) women who had an open myomectomy had sarcoma on histology, compared to 1/514 (0.2%) women who were booked for laparoscopic myomectomy. In the latter case, the diagnosis of sarcoma was made at surgery and an open hysterectomy was performed instead. The sensitivity of ultrasound diagnosis of uterine sarcoma was 85.7% (95% CI 57.2 -98.2) and the specificity was 99.5% (95% CI 98.7 -99.8).
Conclusions: Preoperative ultrasound diagnosis of uterine sarcoma is highly specific. The sensitivity was less than 90% and additional precautions such as in-bag morcellation should be employed to avoid inadvertent peritoneal spread of undiagnosed malignancies. 
